

Sector update

- Cipla (BUY)
- Dr Reddy's (ADD)
- Natco (HOLD from Add)

Pharmaceuticals

Increasing competition for generic *Revlimid*

Cipla has announced settlement of patent litigation with Celgene (subsidiary of Bristol Myers Squibb) for *Revlimid* (lenalidomide). It has become the fourth company to have settled litigations pertaining to this product after Natco Pharma, Dr Reddy's Lab, and Alvogen. Additional settlements with other companies also remain a possibility. Cadila, Apotex, Sun Pharma, Hetero, Mylan and Aurobindo are the other Para IV filers for it. *Revlimid*'s brand sales in the US stood at over US\$6bn in 9MCY20. We believe restriction on volume market share as per settlements will help minimise the impact of growing competition. As per latest information, Natco would launch first in Mar'22 followed by the other three companies whose timelines have not been disclosed.

- **Four companies have settled *Revlimid* litigation; more may follow:** Natco, Alvogen, Dr Reddy's, and Cipla have settled their respective litigations, in that specific order, for launching generic *Revlimid*. There are six more para IV filers and we may observe more of these settlements going forward depending on positioning of generic companies in the litigations. Natco (Teva is the marketing partner) would be the first company to launch generic *Revlimid* in Mar'22 and, as per the settlement, it would be the best positioned to monetise this opportunity. Terms of the settlement for these companies are as below:

Natco/Teva (settled in Dec'15) will launch generic *Revlimid* in Mar'22 with volume market share constraint of mid-single digit in the first full year of launch, with volumes gradually increasing to no more than one-third market share in final year of the settlement deal. Later, unlimited volumes can be sold from 31st Jan'26.

Alvogen (settled in Mar'19) will launch on an undisclosed date after Natco and will have volume market share constraint, with volumes gradually increasing to no more than single-digit share in the final year of deal. Later, unlimited volumes can be sold from 31st Jan'26.

Dr Reddy's (settled in Sep'20) will launch on an undisclosed date after Natco and will have volume market share constraints, which remain undisclosed, up to 31st Jan'26. Later, unlimited volumes can be sold from 31st Jan'26.

Cipla (settled in Dec'20) will launch on an undisclosed date after Natco and will have volume market share constraints, which remain undisclosed, until 31st Jan'26. Later, unlimited volumes can be sold from 31st Jan'26.

- **Impact on stocks:** Key point is volume market share constraints in all settlements, which would help limit the impact of growing competition. However, price erosion could be higher than prior estimates. Hence, we increase our price erosion estimates and marginally lower opportunity value for Dr Reddy's and Natco Pharma.

Cipla: We add Rs28/share for *Revlimid* opportunity, hence we raise the target price to Rs938/share (earlier: Rs910) and maintain **BUY** on the stock.

Dr Reddy's Lab: We lower the *Revlimid* opportunity value by Rs73/share, assuming higher price erosion. We maintain **ADD** with a revised target price of Rs5,412/share (earlier: Rs5,485/share).

Natco Pharma: We lower the *Revlimid* opportunity value by Rs24/share, assuming higher price erosion. Considering the recent run-up in stock price, we downgrade it to **HOLD** from *Add* with a revised target price of Rs974/share (earlier: Rs998/share).

Valuation summary

Company	Reco	CMP (Rs)	TP (Rs)	P/E (x)			EV/EBITDA (x)			RoE (%)		
				FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
Cipla	Buy	756	938	26.3	23.1	20.2	14.0	12.4	10.6	13.8	13.9	14.0
Dr Reddy's	Add	5,016	5,412	30.1	26.4	18.0	17.4	15.2	10.6	16.6	16.6	21.0
Natco	Hold	951	974	31.1	30.3	14.1	23.0	22.1	10.2	14.0	12.9	24.0

Source: I-Sec research

Research Analysts:

Sriram Rath

sriram.rathi@icicisecurities.com

+91 22 6637 7574

Vinay Bafna

vinay.bafna@icicisecurities.com

+91 22 6637 7339

Cipla financial summary (consolidated)

Table 1: Profit & Loss statement

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
Domestic formulations	67,410	75,743	84,533	93,667
Export formulations	92,420	104,343	112,288	120,645
APIs	7,520	8,272	9,099	10,009
Other op. Income	3,970	2,779	2,779	2,779
Total Gross Sales	171,320	191,137	208,699	227,100
Excise duty	-	-	-	-
Total Net Revenue	171,320	191,137	208,699	227,100
YoY Growth%	4.7	11.6	9.2	8.8
Total Op. Exp.	138,735	148,609	162,263	175,435
EBITDA	32,585	42,528	46,435	51,665
Margins %	19.0	22.3	22.3	22.8
YoY Growth%	5.2	30.5	9.2	11.3
Depreciation	11,747	11,124	11,799	12,474
EBIT	20,838	31,404	34,637	39,191
Other Income	3,442	2,328	2,423	2,527
Interest	1,974	1,540	970	490
EO Items	(525)	0	0	0
PBT	21,782	32,192	36,090	41,228
Tax	6,312	9,014	9,744	11,132
Tax Rate (%)	29.0	28.0	27.0	27.0
Minority Interest	5	0	0	0
Reported PAT	15,465	23,178	26,345	30,097
Adj. PAT	15,838	23,178	26,345	30,097
Net Margins (%)	9.2	12.1	12.6	13.3

Source: Company data, I-Sec research

Table 2: Balance sheet

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
Paid-up Capital	1,613	1,613	1,613	1,613
Reserves & Surplus	156,018	176,286	199,722	226,909
Total Equity	157,630	177,899	201,335	228,522
Minority Interest	2,943	2,943	2,943	2,943
Total Debt	28,164	23,164	9,164	7,164
Deferred Liabilities	1,254	1,254	1,254	1,254
Capital Employed	189,992	205,260	214,696	239,883
Current Liabilities	44,236	50,784	54,529	58,809
Total Liabilities	234,228	256,045	269,225	298,692
Net Fixed Assets	107,424	103,800	99,501	94,527
Investments	2,195	2,195	2,195	2,195
Inventory	43,776	46,891	51,200	55,356
Debtors	38,913	43,414	47,403	51,583
Other Current Assets	21,715	23,682	25,426	27,252
Cash and Equivalents	20,204	36,061	43,500	67,778
Total Cur. Assets	124,609	150,049	167,529	201,969
Total Assets	234,228	256,045	269,225	298,692

Source: Company data, I-Sec research

Table 3: Cashflow statement

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
PBT (Adj. for Extraordinary)	21,782	32,192	36,090	41,228
Depreciation	11,747	11,124	11,799	12,474
Net Chg in WC	3,730	(3,137)	(6,385)	(5,977)
Taxes	(8,483)	(9,014)	(9,744)	(11,132)
Others	(65)	101	90	94
CFO	28,711	31,267	31,849	36,688
Capex	(10,177)	(7,500)	(7,500)	(7,500)
Net Investments made	12,100	-	-	-
Others	(882)	-	-	-
CFI	1,040	(7,500)	(7,500)	(7,500)
Change in Share capital	1	-	-	-
Change in Debts	(17,382)	(5,000)	(14,000)	(2,000)
Div. & Div Tax	(6,642)	(2,910)	(2,910)	(2,910)
Others	(1,878)	-	-	-
CFF	(25,900)	(7,910)	(16,910)	(4,910)
Total Cash Generated	3,851	15,857	7,439	24,278
Cash Opening Balance	6,188	10,039	25,896	33,335
Cash Closing Balance	10,039	25,896	33,335	57,613

Source: Company data, I-Sec research

Table 4: Key ratios

(Year ending March 31)

	FY20	FY21E	FY22E	FY23E
Adj EPS	19.6	28.7	32.7	37.3
YoY Growth%	(2.0)	46.3	13.7	14.2
Cash EPS	21.6	30.7	33.9	37.9
EBITDA (%)	19.0	22.3	22.3	22.8
NPM (%)	9.2	12.1	12.6	13.3
Net Debt to Equity (x)	0.1	(0.1)	(0.2)	(0.3)
P/E (x)	38.5	26.3	23.1	20.2
EV/EBITDA (x)	18.9	14.0	12.4	10.6
P/BV (x)	3.9	3.4	3.0	2.7
EV/Sales (x)	3.6	3.1	2.8	2.4
RoCE (%)	8.5	11.9	12.4	13.0
RoE (%)	10.3	13.8	13.9	14.0
RoIC (%)	9.4	13.4	14.9	16.6
Book Value (Rs)	196	221	250	283
DPS (Rs)	3.0	3.0	3.0	3.0
Dividend Payout (%)	12.0	12.0	12.0	12.0
Div Yield (%)	0.4	0.4	0.4	0.4
Asset Turnover Ratio	0.7	0.8	0.8	0.8
Avg Collection days	86	79	79	80
Avg Inventory days	110	111	110	111

Source: Company data, I-Sec research

Dr Reddy's financial summary (consolidated)

Table 5: Profit and Loss statement

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
Global Generics	138,123	158,416	173,472	205,103
PSAI	25,747	33,156	36,471	40,119
Proprietary Products	671	0	0	0
Others	2,830	2,264	2,377	2,496
Net Sales	167,371	193,836	212,321	247,718
Total Revenue	167,371	193,836	212,321	247,718
YoY Growth%	10.1	15.8	9.5	16.7
Total Op. Exp.	132,047	146,477	159,518	174,548
EBITDA	35,324	47,359	52,803	73,169
Margins %	21.1	24.4	24.9	29.5
YoY Growth%	19.6	34.1	11.5	38.6
Depn. & Amortisation	12,472	13,057	13,404	14,182
EBIT	22,852	34,302	39,399	58,987
Other Inc/Interest (net)	2,869	2,608	2,665	2,724
Extraordinary Items	(7,690)	0	0	0
PBT	18,031	36,910	42,063	61,711
Tax	4,998	9,227	10,516	15,428
Tax Rate (%)	27.7	25.0	25.0	25.0
Minority Interest	(6,464)	-	-	-
Reported PAT	19,497	27,682	31,547	46,283
Adjusted PAT	25,055	27,682	31,547	46,283
Net Margins (%)	15.0	14.3	14.9	18.7

Source: Company data, I-Sec research

Table 6: Balance sheet

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
Paid-up Capital	831	831	831	831
Reserves & Surplus	154,157	176,837	201,667	238,095
Total Equity	154,988	177,668	202,498	238,926
Total Debt	22,102	22,102	22,102	22,102
Other non-current liab.	2,860	2,860	2,860	2,860
Capital Employed	179,950	202,630	227,460	263,888
Total Cur. Lia. & Prov.	52,016	60,137	65,743	75,368
Total Liabilities	231,966	262,767	293,202	339,256
Net Fixed Assets	83,985	101,428	100,024	97,842
Deferred tax asset	11,939	11,939	11,939	11,939
Investments	3,091	3,091	3,091	3,091
Inventory	35,066	39,947	43,756	51,051
Debtors	50,278	51,305	56,197	65,566
Other Current Assets	21,867	24,458	26,267	29,732
Cash and Equivalents	25,740	30,600	51,929	80,036
Total Cur. Assets	132,951	146,309	178,149	226,384
Total Assets	231,966	262,767	293,202	339,256

Source: Company data, I-Sec research

Table 7: Cashflow statement

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
PBT (Adj. for EO items)	18,031	36,910	42,063	61,711
Depreciation	12,472	13,057	13,404	14,182
Net Chg in WC	(12,357)	(3,282)	(6,876)	(14,493)
Taxes	(7,105)	(9,227)	(10,516)	(15,428)
Others	18,800	2,906	1,970	3,991
CFO	29,841	40,363	40,046	49,962
Capex	(5,725)	(30,500)	(12,000)	(12,000)
Net Investments made	(214)	-	-	-
Others	1,016	-	-	-
CFI	(4,923)	(30,500)	(12,000)	(12,000)
Change in Share capital	4	-	-	-
Change in Debts	(19,165)	-	-	-
Div. & Div Tax	(3,916)	(5,003)	(6,717)	(9,855)
Others	(2,016)	-	-	-
CFF	(25,093)	(5,003)	(6,717)	(9,855)
Total Cash Generated	(175)	4,860	21,328	28,107
Cash Opening Balance	2,228	2,053	6,913	28,242
Cash Closing Balance	2,053	6,913	28,242	56,349

Source: Company data, I-Sec research

Table 8: Key ratios

(Year ending March 31)

	FY20	FY21E	FY22E	FY23E
Adj EPS (Rs)	112.0	166.8	190.0	278.8
YoY Growth%	9.7	48.9	14.0	46.7
Cash EPS (Rs)	187.1	245.4	270.8	364.2
EBITDA - Core (%)	21.1	24.4	24.9	29.5
NPM (%)	15.0	14.3	14.9	18.7
Net Debt to Equity (x)	(0.0)	(0.0)	(0.1)	(0.2)
P/E (x)	44.8	30.1	26.4	18.0
EV/EBITDA Core (x)	23.5	17.4	15.2	10.6
P/BV (x)	5.4	4.7	4.1	3.5
EV/Sales (x)	5.0	4.3	3.8	3.1
ROCE (%)	10.3	14.5	14.7	18.8
ROE (%)	12.6	16.6	16.6	21.0
ROIC (%)	11.9	17.0	18.1	25.7
Book Value (Rs)	933.7	1,070.3	1,219.9	1,439.3
DPS (Rs)	20.7	25.0	33.6	49.3
Dividend Payout (%)	17.7	15.0	17.7	17.7
Div Yield (%)	0.4	0.5	0.7	1.0
Asset Turnover Ratio	0.7	0.8	0.8	0.8
Avg Collection days	97	97	97	97
Avg Inventory days	75	75	75	75

Source: Company data, I-Sec research

Natco financial summary (consolidated)

Table 9: Profit & Loss statement

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
Domestic formulations	3,552	5,328	5,328	5,861
Export formulations	5,405	4,999	5,727	6,397
APIs	9,334	10,756	11,269	20,237
Other Operating Income	859	2,445	1,039	1,143
Total Gross Sales	19,150	23,528	23,363	33,638
Excise duty	-	-	-	-
Total Net Revenue	19,150	23,528	23,363	33,638
YoY Growth%	(8.6)	22.9	(0.7)	44.0
Total Op. Exp.	13,324	16,254	15,860	17,702
EBITDA	5,826	7,273	7,503	15,935
Margins %	30.4	30.9	32.1	47.4
YoY Growth%	(26.7)	24.8	3.2	112.4
Depreciation	998	1,148	1,281	1,440
EBIT	4,828	6,125	6,222	14,495
Other Income	1,074	1,128	1,218	1,315
Interest	215	158	158	158
EO Items	0	0	0	0
PBT	5,687	7,095	7,282	15,653
Tax	1,106	1,561	1,602	3,444
Tax Rate (%)	19.4	22.0	22.0	22.0
Minority Interest	(27)	(27)	(27)	(27)
Reported PAT	4,608	5,561	5,707	12,236
Adj. PAT	4,608	5,561	5,707	12,236
Net Margins (%)	24.1	23.6	24.4	36.4

Source: Company data, I-Sec research

Table 10: Balance sheet

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
Paid-up Capital	364	364	364	364
Reserves & Surplus	37,371	41,594	45,927	55,218
Total Equity	37,735	41,958	46,291	55,582
Minority Interest	112	85	58	31
Total Debt	3,159	3,159	3,159	3,159
Deferred Liabilities	259	259	259	259
Capital Employed	41,265	45,461	49,767	59,031
Current Liabilities	4,613	6,340	5,897	7,712
Total Liabilities	45,878	51,800	55,664	66,743
Net Fixed Assets	21,024	23,876	26,595	29,156
Investments	836	836	836	836
Inventory	5,580	6,807	6,642	7,414
Debtors	5,513	6,773	6,726	9,684
Other Current Assets	12,440	13,087	13,063	14,582
Cash and Equivalents	485	421	1,802	5,072
Total Cur. Assets	24,018	27,088	28,233	36,751
Total Assets	45,878	51,800	55,664	66,743

Source: Company data, I-Sec research

Table 11: Cashflow statement

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
PBT (Adj. for Extraordinary)	5,687	7,095	7,282	15,653
Depreciation	998	1,148	1,281	1,440
Net Chg in WC	(410)	(1,232)	(212)	(3,020)
Taxes	(1,078)	(1,561)	(1,602)	(3,444)
Others	(1,239)	(176)	7	(414)
CFO	3,958	5,274	6,755	10,215
Capex	(3,365)	(4,000)	(4,000)	(4,000)
Net Investments made	530	-	-	-
Others	1,165	-	-	-
CFI	(1,670)	(4,000)	(4,000)	(4,000)
Change in Share capital	58	-	-	-
Change in Debts	(809)	-	-	-
Div. & Div Tax	(1,536)	(1,339)	(1,374)	(2,945)
Others	(2,136)	-	-	-
CFF	(4,423)	(1,339)	(1,374)	(2,945)
Total Cash Generated	(2,135)	(64)	1,381	3,270
Cash Opening Balance	2,795	660	596	1,977
Cash Closing Balance	660	596	1,977	5,247




Source: Company data, I-Sec research

Table 12: Key ratios

(Year ending March 31)

	FY20	FY21E	FY22E	FY23E
Adj EPS	25.3	30.6	31.4	67.2
YoY Growth%	(28.5)	20.7	2.6	114.4
Cash EPS	39.9	30.8	36.9	38.4
EBITDA - Core (%)	30.4	30.9	32.1	47.4
NPM (%)	24.1	23.6	24.4	36.4
Net Debt to Equity (x)	0.1	0.1	0.0	(0.0)
P/E (x)	37.6	31.1	30.3	14.1
EV/EBITDA Core (x)	28.7	23.0	22.1	10.2
P/BV (x)	4.6	4.1	3.7	3.1
EV/Sales (x)	8.7	7.1	7.1	4.8
RoCE (%)	11.7	12.8	12.0	22.2
RoE (%)	12.7	14.0	12.9	24.0
RoIC (%)	12.5	13.1	12.4	23.8
Book Value (Rs)	207	231	254	305
DPS (Rs)	5.8	6.1	6.3	13.4
Dividend Payout (%)	22.7	20.0	20.0	20.0
Div Yield (%)	0.6	0.6	0.7	1.4
Asset Turnover Ratio	0.4	0.5	0.4	0.5
Avg Collection days	101	95	105	89
Avg Inventory days	104	96	105	76

Source: Company data, I-Sec research

Price charts**Cipla****Dr Reddy's Lab****Natco Pharma**

Source: Bloomberg

In case of industry/sector reports or a report containing multiple stocks, the rating/recommendation for a particular stock may be based on the last released stock specific report for that company.

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #37-16 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

*New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return*

ANALYST CERTIFICATION

I/We, **Sriram Rath, CA; Vinay Bafna, MBA**; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.